Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
Context Therapeutics Inc. (CNTX)
Company Research
Source: GlobeNewswire
PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced a poster regarding the Company’s clinical asset, CT-95, a mesothelin (“MSLN”) x CD3 TCE will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL. Context will present data highlighting the selection of the first-in-human dose of CT-95, using the minimal anticipated biological effect level (“MABEL”) approach, as required for immune agonist drugs. This is the dose level expected to lead to a
Read more
Impact Snapshot
Event Time:
CNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTX alerts
High impacting Context Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
CNTX
News
- Context Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth [Yahoo! Finance]Yahoo! Finance
- Context Therapeutics Inc. (NASDAQ: CNTX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.MarketBeat
- Context Therapeutics Inc. (NASDAQ: CNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Context Therapeutics Reports Full Year 2024 Operating and Financial ResultsGlobeNewswire
CNTX
Sec Filings
- 3/20/25 - Form S-8
- 3/20/25 - Form 10-K
- 2/28/25 - Form 8-K
- CNTX's page on the SEC website